Home                  Mission                  Services                  Special Service                  Competencies

WELCOME TO 

KellSa s.a.s.

SPECIAL SERVICE

KellSa s.a.s. has a unique specialty within the area of anti-thrombotic research and development.

This is the ex vivo models of thrombus formation employing non-anticoagulated

human blood and relevant vascular surfaces at blood flow conditions mimicking those of

healthy and diseased veins and arteries, e.g. arteries with various degrees of occluding

stenoses.

A library of antithrombotic efficacy data is available at KellSa s.a.s. from studies on:

· registered antithrombotic drugs

· novel antithrombotic strategies

· antithrombotic drug candidates

· experimental antithrombotics

The models are also employed for studies of haemostasis and pro-thrombotic states.

KellSa s.a.s. provides manufacturing of these non-commercial models and offer special

training of local research teams to operate these unique blood flow devices.

Advantages with these models are:

· Target identification and validation in human models

· Early proof of concept in human models

· Early selection of small molecules / peptides / proteins with antithrombotic efficacy in human models

· Early identification of antithrombotic efficacy in human models; e.g. venous versus arterial thrombus formation, thus blood shear rate dependent antithrombotic efficacy

· Dose finding studies and biomarker identification in ex vivo human models before the commencement of clinical trials in man

· Significant reduction of animal studies in R&D – a major and important ethical development!

· Reduction of attrition rate due to ( I ) target identification and validation in human models, ( II ) early ex vivo proof of concept in man, ( III ) ex vivo dose-response findings in man before first clinical trials, ( IV ) ex vivo identification of biomarkers before first clinical trials, ( V ) identification of possible shear rate dependent antithrombotic efficacy as support for selection of patients for phase 2 and 3 clinical trials and ( VI ) significant reduction of animal in vivo studies